Stretching Scarce Resources: The 340B Drug Pricing Program, What It Was Written to Do and How Its Aims Can Be Evaluated
Student Name
American College of Education
HLTH5453: Health Policy Evaluation and Development
Module 1 Assignment
Instructor Name
November 1, 2027
Origin and Mechanics
The 340B Drug Pricing Program takes its name from a section of the Public Health Service Act added by the Veterans Health Care Act of 1992. It requires drug manufacturers that participate in Medicaid to sell outpatient drugs to certain health care organizations, called covered entities, at or below a ceiling price set by a statutory formula. Covered entities include federally qualified health centers, Ryan White HIV/AIDS clinics and other federal grantees, as well as hospitals that meet eligibility thresholds, most commonly general acute care hospitals whose Medicare disproportionate share hospital adjustment exceeds 11.75 percent. The Affordable Care Act later extended eligibility to critical access hospitals, rural referral centers, sole community hospitals and freestanding cancer hospitals.
The program's financial logic is simple and has large consequences. A covered entity buys a drug at the discounted 340B price but is generally paid by insurers at the ordinary rate, so the difference becomes revenue for the entity. The program is administered by the Health Resources and Services Administration's Office of Pharmacy Affairs, and it does not require covered entities to report how much they earn from the discount or how they use it. The program was built as a transfer of value to safety-net providers, and it left the use of that value almost entirely to the providers themselves.
The Stated Aim
The aim most often quoted comes from the House committee report that accompanied the 1992 legislation, which described the purpose as enabling covered entities to stretch scarce federal resources as far as possible, reaching more eligible patients and providing more comprehensive services. That phrasing is broad. It does not specify which patients are eligible patients, whether the resources should reach low-income or uninsured patients directly or what counts as more comprehensive services. The law itself defines who may participate but does not define how the savings should be used.
Conti and Bach (2014) describe the program's original intent as helping low-income and uninsured patients, and they note that critics contend some hospitals use the discounts to generate profits rather than to invest in care for the poor or pass savings to patients. The stated aim, in other words, is about capacity: giving safety-net providers more resources. It is not written as an aim about particular outcomes for particular patients, which matters for how the program can be evaluated.
Implicit Aims and Where They Diverge
Around the stated aim, other aims have grown up in public debate, and different parties emphasize different ones. Patient advocates and some policymakers treat the program as intended to lower drug costs for low-income and uninsured patients at the point of care. Hospital associations emphasize its role in sustaining safety-net hospitals' overall finances, including services that lose money. Manufacturers argue that it was meant to serve a narrow group of vulnerable patients and has expanded well beyond that. Each claim finds some support in the broad language of the original report, and none is the only reading.
The divergence has consequences because the program has grown. Conti and Bach (2014) matched data on 960 hospitals and nearly 4,000 affiliated clinics registered with the program in 2012 to community data and found that hospital-affiliated clinics that registered in 2004 or later served communities that were wealthier and had higher rates of health insurance than those served by earlier registrants. If the aim is capacity for safety-net institutions, that pattern may be acceptable. If the aim is care for low-income patients, it is a sign that the program's benefits are drifting away from them. Much of the argument about 340B is not about evidence at all but about which of its aims the evidence should be measured against.
Turning Aims Into Evaluable Objectives
An aim cannot be evaluated until it is translated into an objective with a measure. Four objectives follow from the stated and implicit aims. The first, from the capacity aim, is that covered entities receive meaningful financial benefit from the program, measurable as the value of 340B savings relative to their operating budgets. The second, from the patient-care aim, is that the benefit results in more or better care for low-income patients, measurable as changes in charity care, services in underserved areas or the share of low-income patients served. The third, from the implicit aim of lowering patient costs, is that low-income and uninsured patients pay less for their outpatient drugs, measurable at the pharmacy counter. The fourth, from concerns about expansion, is that program growth remains concentrated among providers serving low-income communities, measurable by the characteristics of the communities served by new participants.
The first objective can be evaluated with existing data. The second and third are harder, because the program does not require entities to report how they use savings or what patients pay, which is itself an important finding for any evaluation. The fourth can be tested with public registration data linked to census data, as Conti and Bach (2014) did.
What the Aims Imply for Evaluation
Two lessons follow for the evaluation to come. First, an evaluation of 340B has to state which aim it is judging the program against, or its conclusion will be read as taking a side in a dispute about purpose rather than evidence. A finding that hospitals earn substantial revenue from the program is a success under the capacity aim and a warning under the patient-care aim. Second, the program's design limits what can be known. Because entities are not required to report savings or their use, an evaluator must rely on indirect evidence, such as changes in hospital behavior around the eligibility threshold, rather than direct accounting. The next module will set criteria before reaching any verdict, so that the evidence is judged against a standard chosen in advance rather than one chosen to fit a conclusion.
Early evidence shows how much the choice of aim matters. Using the eligibility threshold as a natural experiment, Desai and McWilliams (2018) found that hospital eligibility for 340B was associated with more hospital-employed hematologist-oncologists and more hospital-billed parenteral drug claims in oncology and ophthalmology, but not with clear evidence of expanded care or lower mortality among low-income patients in the hospitals' service areas. Federal auditors have also raised concerns about oversight, particularly of the contract pharmacies through which many covered entities now dispense 340B drugs (U.S. Government Accountability Office [GAO], 2018). Both findings bear on the patient-care and expansion objectives, and neither answers the capacity objective, which is exactly why the next module must decide which objectives it will judge before it reads the evidence.
Conclusion
The 340B Drug Pricing Program was written to give safety-net providers more resources by requiring discounted outpatient drug prices, and its stated aim, stretching scarce federal resources to reach more eligible patients, is broad enough to support several readings. The controversy around the program arises largely from the gap between that capacity aim and later expectations about direct benefit to low-income patients, a gap widened by the program's growth into wealthier communities and by the absence of reporting on how savings are used. Translating each aim into a measurable objective is the necessary first step toward an evaluation that can say, clearly and fairly, whether the program meets the purpose it was written for.
References
Conti, R. M., & Bach, P. B. (2014). The 340B drug discount program: Hospitals generate profits by expanding to reach more affluent communities. Health Affairs, 33(10), 1786-1792. https://doi.org/10.1377/hlthaff.2014.0540
Desai, S., & McWilliams, J. M. (2018). Consequences of the 340B drug pricing program. New England Journal of Medicine, 378(6), 539-548. https://doi.org/10.1056/NEJMsa1706475
U.S. Government Accountability Office. (2018). Drug discount program: Federal oversight of compliance at 340B contract pharmacies needs improvement (GAO-18-480).
How this HLTH 5453 Module 1 example is structured
HLTH 5453 Module 1 often starts with one enacted policy and the aims it was written to serve; your classroom's instructions decide the policy and the depth of analysis. This example describes the policy's origin and mechanics first, because aims cannot be judged without knowing how the policy operates. It then distinguishes the stated aim from the implicit aims that grew around it, and shows how the gap between them explains much of the controversy. A final section converts each aim into an evaluable objective, which sets up the criteria-based evaluation in the next module.
HLTH5453 Module 1 questions, answered
What does HLTH5453 Module 1 usually ask for?
HLTH5453 Module 1 often asks students to select one enacted health policy and analyze its purpose: what problem it was designed to address, how it works and what aims it was written to serve. Many sections expect the aims to be identified from legislative or official sources. Your classroom's instructions decide the policy options and the format of the analysis.
What is the difference between a policy's stated and implicit aims?
Stated aims come from the law, its legislative history or official guidance. Implicit aims are purposes that stakeholders later attribute to the policy, sometimes reasonably and sometimes to support their position. Separating them matters because an evaluation will reach different verdicts depending on which aim it measures the policy against.
How do I turn a policy aim into something that can be evaluated?
Write each aim as an objective with a measurable indicator and a data source. An aim such as helping low-income patients becomes an objective like increasing the share of low-income patients served, measured with hospital or claims data. Note where the policy's design makes the needed data unavailable, since that is itself an evaluation finding.
Write yours, or have the desk draft it
This paper is an original model document written by our desk, not a submitted student paper and not an official American College of Education document. Read it for the moves, then write your own to the instructions in your classroom. If you want one built to your exact prompt and rubric, the first custom sample is free and arrives in 24 to 48 hours.